Evidence map›Paper›PMID 39346629›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2024

The Clinical Characteristics, Treatment and Prognosis of Tuberculosis-Associated Chronic Obstructive Pulmonary Disease: A Protocol for a Multicenter Prospective Cohort Study in China.

Zhihan Jiang, Yingying Dai, Jing Chang, Pingchao Xiang, Zhenyu Liang, Yan Yin, Yongchun Shen, Ruiying Wang, Bianba Qiongda, Hongling Chu and 4 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Advances in the awareness of tuberculosis-associated chronic obstructive pulmonary disease.Chinese medical journal pulmonary and critical care medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhihan Jiang *Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People's Republic of China.ORCID 0000-0002-7943-464X
Yingying Dai *School of Basic Medical Sciences, Peking University, Beijing, People's Republic of China.
Jing ChangSchool of Basic Medical Sciences, Peking University, Beijing, People's Republic of China.
Pingchao XiangDepartment of Respiratory and Critical Care Medicine, Peking University Shougang Hospital, Beijing, People's Republic of China.
Zhenyu LiangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, GuangZhou, People's Republic of China.ORCID 0000-0002-8746-315X
Yan YinDepartment of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, People's Republic of China.ORCID 0000-0002-7266-3554
Yongchun ShenDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, People's Republic of China.ORCID 0000-0002-8142-1792
Ruiying WangDepartment of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Taiyuan, People's Republic of China.ORCID 0000-0001-6224-8480
Bianba QiongdaDepartment of Respiratory and Critical Care Medicine, Tibet Autonomous Region People's Hospital, Lhasa, People's Republic of China.
Hongling ChuClinical Epidemiology Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Nan LiClinical Epidemiology Research Center, Peking University Third Hospital, Beijing, People's Republic of China.ORCID 0000-0003-4231-8853
Xiaoyan GaiDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People's Republic of China.
Ying LiangDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People's Republic of China.
Yongchang SunDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People's Republic of China.

Funding

China International Medical Foundation Z-2017-24-2301
6 · The paper itself

Abstract

Background: Tuberculosis and chronic obstructive pulmonary disease (COPD) are significant public health challenges, with pulmonary tuberculosis recognized as a pivotal risk factor for the development of COPD. Tuberculosis-associated COPD is increasingly recognized as a distinct phenotype of COPD that potentially exhibits unique clinical features. A thorough understanding of the precise definition, clinical manifestations, prognosis, and most effective pharmacological strategies for tuberculosis-associated COPD warrants further investigation. Methods: This prospective, observational cohort study aims to enroll over 135 patients with tuberculosis-associated COPD and 405 patients with non-tuberculosis-associated COPD, across seven tertiary hospitals in mainland China. The diagnosis of tuberculosis-associated COPD will be established based on the following criteria: (1) history of pulmonary tuberculosis with standard antituberculosis treatment; (2) suspected pulmonary tuberculosis with radiological evidence indicative of tuberculosis sequelae; (3) no definitive history of pulmonary tuberculosis but with positive interferon-gamma release assay results and radiological signs suggestive of tuberculosis. At baseline, demographic information, medical history, respiratory questionnaires, complete blood count, interferon-gamma release assays, medications, spirometry, and chest computed tomography (CT) scans will be recorded. Participants will be followed for one year, with evaluations at six-month intervals to track the longitudinal changes in symptoms, treatment, lung function, and frequencies of COPD exacerbations and hospitalizations. At the final outpatient visit, additional assessments will include chest CT scans and total medical costs incurred. Discussion: The findings of this study are expected to delineate the specific characteristics of tuberculosis-associated COPD and may propose potential treatment options for this particular phenotype, potentially leading to improved clinical management and patient outcomes.

Indexed as

Antitubercular AgentsLungPulmonary Disease, Chronic ObstructiveTuberculosis, PulmonaryChinaDisease ProgressionHumansMulticenter Studies as TopicObservational Studies as TopicPrognosisProspective StudiesResearch DesignRisk FactorsTime FactorsTreatment OutcomeAntitubercular Agentschronic obstructive pulmonary diseaseCOPDprotocolpulmonary tuberculosistuberculosis-associated COPD

Identifiers

PMID39346629
PMCPMC11439353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.